Cerecor Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

Cerecor (NASDAQ: CERC) today announced financial results for the fourth quarter and full year 2017. Net Revenues for the year ended 2017 were $27.8 million. As of December 31, 2017, the Company had $43.1 million in total assets including cash and cash equivalents of $2.5 million, accounts receivable of $3.3 million, and escrowed receivable of $3.8 million. Total liabilities were $15.3 million and Total Stockholder’s equity was $27.9 million.

As quoted in the press release:

“These are exciting times at Cerecor as we close out 2017 with strong financial performance that has resulted from our ability to execute on key strategic transactions,” said Peter Greenleaf, Chief Executive Officer of Cerecor. “We are entering 2018 with strong momentum and will work to continue our growth as we continue to execute on key business objectives, such as the recent acquisition of the marketed pediatric portfolio from Avadel Pharmaceuticals and entering our lead compound, CERC-301, into a Phase I safety study for Neurogenic Orthostatic Hypotension (“nOH”). I believe Cerecor is well-positioned to take advantage of vast opportunities as a fully integrated pediatric pharmaceutical company with a platform to develop compounds that can make a true difference in patients suffering from rare or orphan diseases.”

Click here to read the full press release.